A new cohort of obesity drugs, called GLP1 receptor agonists, are so effective and safe that they will likely be put into widespread use for the treatment of obesity and achieve unparalleled success in the treatment of this disease—on par with bariatric surgery, but without the surgery. In this video I discuss the latest science and the promise of these drugs—as well as two other new classes of drugs that show similar (and synergistic) promise.Links to references, in the order that they were discussed:STEP1, semaglutide:https://www.nejm.org/doi/10.1056/NEJMoa2032183STEP4, semaglutide:https://jamanetwork.com/journals/jama/fullarticle/2777886Semaglutide plus cagrilintide:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X/fulltextMeta-analysis of long-term outcomes:https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858719302499Tirzepatide clinical trial registration:https://clinicaltrials.gov/ct2/show/NCT04184622Bimagrumab:https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2774903Small molecule GLP1 receptor agonist:https://diabetesjournals.org/diabetes/article/69/Supplement_1/353-OR/56321/353-OR-Oral-Small-Molecule-GLP-1R-Agonist-PF===Like, comment, subscribe.For more, find me at:PODCAST The Kevin Bass ShowYOUTUBE https://www.youtube.com/user/kbassphiladelphiaWEBSITE http://thedietwars.comTWITTER https://twitter.com/kevinnbass/https://twitter.com/healthmisinfo/INSTAGRAM https://instagram.com/kevinnbass/TIKTOK https://tiktok.com/@kevinnbassAnd above all, please donate to support what I do:PATREON https://patreon.com/kevinnbass/DONATE https://thedietwars.com/support-me/